You are warned. Sinovac turns umno leaders into mandarin speakers.

[Hypocrite-The]

If the Chicom vaccine soo good,,,why is the population not 100% vaccinated? and why must they buy ang mor vaccines? this just proves that Chicom vaccine is shit and AMDK



China has secured 100 million doses of BioNTech’s vaccine. Why hasn’t it approved the jab yet?
BY
GRADY MCGREGOR
March 20, 2021 6:00 PM GMT+8

Refrigerated shipping containers carrying the BioNTech vaccine, imported by Fosun Pharma, in transport at the Hong Kong International Airport, Feb. 25, 2021.JEROME FAVRE—EPA/BLOOMBERG/GETTY IMAGES
Chinese authorities have yet to approve the COVID-19 vaccine produced by German maker BioNTech and distributed locally by Chinese firm Fosun Pharma. The delay means China can’t access 100 million doses of the proven and effective COVID-19 vaccine it has procured as the country ramps up an ambitious effort to inoculate hundreds of millions of people at home and abroad in coming months.
Since first releasing data last November, BioNTech’s mRNA vaccine has become the gold standard of COVID-19 vaccines. BioNTech and Pfizer, the U.S. pharmaceutical giant and BioNTech’s distribution partner outside China, said it was 95% effective in preventing COVID-19 infections, a claim that was later backed up in both peer-reviewed medical journals and in real-world outcomes.
Some 72 countries have approved the BioNTech vaccine, and it was the first COVID-19 vaccine authorized for use by the World Health Organization (WHO) in December. But China has remained a notable holdout in granting approval for the jab even though Fosun secured over 100 million doses last December to deploy in the Chinese market.

Subscribe to Eastworld for weekly insight on what’s dominating business in Asia, delivered free to your inbox.
In a December statement, Fosun said the vaccines initially will be manufactured in Germany, though the two sides reportedly have been in talks to build an additional manufacturing facility in China.

Approving BioNTech’s vaccine could help speed up China’s vaccination campaign and ease supply constraints on other Chinese manufacturers. But Beijing may see unleashing a foreign-made vaccine domestically as undermining the interests of China’s own homegrown competitors.
The trials
In most of the world, BioNTech is partnering with Pfizer to distribute its COVID-19 vaccine. In mainland China, Hong Kong, Macau, and Taiwan, BioNTech is instead relying on Shanghai-based Fosun, according to a deal struck in March 2020.
BioNTech and Fosun’s partnership has been rocky in Taiwan. Beijing and Taipei have provided conflicting accounts of why Fosun and BioNTech haven’t struck a deal to supply the island with the vaccine, despite Taiwan’s interest in the shots.
But the pairing has proved fruitful elsewhere.
In January, Hong Kong authorities approved the vaccine for use in the city, citing data shared by BioNTech and recommendations from the WHO. Fosun delivered the first doses of BioNTech’s vaccine to Hong Kong in February and began distributing doses to city residents on March 10.

In mainland China, meanwhile, the vaccine’s approval remains in limbo.
On Nov. 24, Fosun launched Phase II trials of BioNTech’s vaccine in China, testing its safety on a group of 960 volunteers, though similar trials in the U.S. and Germany already have concluded the vaccine is safe.
China typically requires foreign vaccine makers to conduct safety trials in China before approval, says Jennifer Bouey, an epidemiologist and China health policy expert at Rand Corporation. But in 2016 China started relaxing requirements for foreign drugmakers, which would allow the government to approve a vaccine without conducting safety trials in China first.
Fosun said the trial was an important step in meeting China’s regulatory requirements. The clinical study “provides key data for the launch of the vaccine in China,” Aimin Hui, Fosun Pharma’s chief medical officer, said in a November statement.
Fosun and BioNTech did not return Fortune’s request for comment.

Bouey says the vaccine’s trials in China could be completed any day since such tests typically take between three and six months.
Yanzhong Huang, a senior fellow in global health at the Council on Foreign Relations, argues the safety trials should be an unnecessary hurdle for Fosun given the WHO’s approval of the vaccine and its authorization in dozens of other countries.
“It’s surprising that instead of approving it right away, China is asking Fosun to repeat the same tests that have already been done elsewhere,” says Huang. “The data is already there.”
China’s National Health Commission did not respond to Fortune’s question on whether it is considering bypassing the safety trials and accepting the WHO’s recommendation.
The politics
China’s delay in approving the vaccine may involve more than regulatory concerns.

In January, Chinese state media outlets—including China’s largest newspaper, People’s Daily—published articles questioning the safety of BioNTech’s vaccine amid reports that elderly people in Norway had died after getting injected (Norwegian authorities found no link between the injections and the deaths.)
“We are in a time when vaccine use itself is becoming politicized,” says Huang. “You have seen state media promoting the safety and efficacy of the domestic Chinese vaccines, and discrediting the foreign vaccines.”
On March 8, Chinese foreign minister Wang Yi spoke out against vaccine nationalism but touted the efforts of Chinese vaccine producers. “The safety and effectiveness of Chinese vaccines are earning recognition across the world,” he said.
China has approved five vaccines for domestic use, but none of China’s vaccine makers have published late-stage trial data in peer-reviewed medical journals proving that they are effective. The latest COVID-19 vaccine approved for the Chinese public was developed by Anhui Zhifei Longcom Biopharmaceutical and the Chinese Academy of Sciences. The two entities have yet to release any data from Phase III clinical trials.
The public health benefits of approving BioNTech’s effective and proven vaccine are obvious, but in such a politicized environment the optics of releasing BioNTech’s vaccine domestically may be unpalatable for Chinese authorities, Bouey says.

Chinese authorities may want to avoid the possibility of the BioNTech vaccine proving more popular than the domestic shots, Bouey says.
“The rich and powerful could grab BioNTech’s vaccine first and cause social tension,” says Bouey.
The campaign
Still, the pressure on China to approve the BioNTech vaccine may increase as Chinese vaccine manufacturers feel the squeeze.
China has set a goal to inoculate over half a billion of its citizens by the end of July. Beijing also has committed to sending at least 560 million doses to low- and middle-income countries around the world as part of its vaccine diplomacy campaign.
Currently, China is relying on homegrown vaccine makers like Sinovac, Sinopharm, and CanSino to fulfill those pledges. Together, the companies are exporting vaccines to at least 43 countries. But experts note the manufacturers are facing supply constraints amid rising global demand.

Ernan Cui, a China consumer analyst at Gavekal Dragonomics, said in a research note that China has the capacity to produce 460 million vaccine doses in the next few months, but that China’s actual output may prove significantly lower as manufacturers struggle to source products like vaccine vials.
Approving the BioNTech vaccine could help ease that pressure by adding the 100 million doses bought by Fosun to China’s domestic supply.
“China’s production [capacity] is slow compared to the urgent and unprecedented quantity of demand from domestic needs and countries they have signed contracts with,” says Bouey. “Additional vaccine supplies would be helpful.”

 

[Hypocrite-The]

https://www.politico.eu/article/everything-you-need-to-know-china-coronavirus-vaccines/






26 eud for 1 shot of chicom vaccine? sure or not? that is more expensive than the ang mor ones


Everything you need to know about China’s coronavirus vaccines
At least 25 countries and territories around the world — largely in Asia and the Middle East — are using Chinese vaccines.

China has been one of the leaders in developing coronavirus vaccines during the pandemic | Kevin Frayer/Getty Images

BY JILLIAN DEUTSCH, HELEN COLLIS AND STUART LAU
March 8, 2021 5:48 pm

• Share on Facebook
• Share on Twitter
• Share on Linkedin
• Mail
• Print

PRESS PLAY TO LISTEN TO THIS ARTICLE

Voiced by Amazon Polly
Move over, Sputnik. The next coronavirus vaccines really causing a stir in Europe are from China.
Polish President Andrzej Duda jumped on the phone to ask his Chinese counterpart Xi Jinping for doses; the Czech Republic just placed an order; and Hungarian Prime Minister Viktor Orbán gave China’s vaccines the biggest EU endorsement by getting one himself.
European capitals, stuck in sluggish vaccination campaigns, are increasingly looking outside the EU for doses — and Beijing is happy to fill the void.

Chinese vaccines already make up 32 percent of Hungary’s total vaccine supply — far more than Russia’s Sputnik V, which accounts for less than 3 percent. And Hungary is just one of at least 25 countries around the world — largely in Asia and the Middle East — using Chinese vaccines. Beijing has promised a half-billion doses to 45 countries, according to a tally from the Associated Press.
For countries with a history of tension, or even conflict, with Moscow, the Chinese vaccines have a simple, added benefit: They're not made in Russia.
China has been one of the leaders in developing coronavirus vaccines throughout the pandemic, having now approved for use four homegrown vaccines. Three of them use an older, tried-and-true method — and boast impressive supply projections.
But the Chinese jabs are no magic bullet. The efficacy data supporting the vaccines is neither public nor peer-reviewed, and many worry that some of them might not be as effective as their Western counterparts. EU countries that have or will use the vaccines are doing so without the European Medicines Agency’s sign-off — meaning they must assume liability if an issue arises later.
Meanwhile, China’s focus on vaccine deliveries abroad has prompted accusations that Beijing is deploying the jabs as a diplomatic tool — an assertion it denies — and that it's ignoring domestic vaccinations.
From efficacy data to manufacturing capacity to vaccine diplomacy, POLITICO has you covered with everything you need to know about the leading Chinese vaccines.

Which vaccines has China made?
China has led in vaccine development throughout the pandemic. Along with the four approved, at least another eight are currently in human trials, and far more are in pre-clinical development, according to the World Health Organization.
The four most advanced include three inactivated coronavirus vaccines: One is CoronaVac, developed by biotech company Sinovac; two more are from state-owned Sinopharm, with one developed at the Beijing Institute of Biological Products, and the other at the Wuhan Institute of Biological Products.
CanSino, meanwhile, has developed a single-dose viral vector vaccine — similar technology to the vaccines developed by Johnson & Johnson, Oxford/AstraZeneca and Sputnik — with the Chinese military.
What are the pros and cons of inactivated virus vaccines?
Inactivated virus vaccines, originally developed by Louis Pasteur in 1904 for anthrax, have been around for a century. They work by taking the whole virus and then killing it — either by heating it up to high temperatures or using radiation or chemicals — so that it no longer has any function. This dead virus is injected to trigger an immune response.
Today, the process is used for many vaccines that protect against polio and the flu. There's a wealth of data supporting the safety of this approach, and it’s generally shown to be highly effective, although each coronavirus vaccine using this approach boasts a different efficacy rate against COVID-19.
Overall, the technology looks promising. Scientists believe that vaccines using a version of the whole coronavirus may generate a broader immune response, including producing antibodies in the mucosal membrane in the nose and throat. This could have a greater impact on preventing transmission.















































































Departing Brits debate — Huawei fallout — EU budget crunch _ POLITICO EU Confidential





"If you have an immune response that limits the amount of viral shedding [in the nose and throat], that will limit the amount of virus in the aerosol you produce when you talk or breathe," said Julian Tang, an honorary associate professor and clinical virologist at the University of Leicester. "That will reduce the risk of transmission."
The catch, he noted, is that these vaccines can be associated with increased risk of disease-like side effects — and the data from China on this has been very limited.
On the plus side, vaccines that induce a broader immune response may also be more effective against emerging new strains of the virus.
“These types of vaccines can generate a broader immunity against different variants because they contain the entire virus, not just a part of the virus,” said Zoltán Kis, research associate at the Future Vaccines Hub at Imperial College London.
Beijing/Sinopharm has tested its vaccine’s ability to neutralize novel coronavirus strains from different sources around the world, which showed the vaccine offers “broad-spectrum protection and has good cross-neutralization effect on strains from different regions of the world,” chairman Liu Jingzhen said recently.
There's only one producer in Europe using the same technology for now: Valneva, a French vaccine producer that has deals with the U.K. and another in the works with the EU.

CanSino’s vaccine, meanwhile, uses the more modern viral vector technology, which deploys a harmless virus as a vector to deliver DNA into the muscle cells and manufactures a tiny part of the coronavirus called the spike protein. This fragment of the virus is enough for the body to generate an immune response against the virus.
What does the data show?
China made headlines last summer when it began using two of its vaccines on health workers and the military before conducting large-scale Phase 3 efficacy trials. Since then, tens of millions of people have gotten the jabs before their approval by regulators.
A broad concern, however, is that the data supporting the vaccines' efficacy has often been patchy and not harmonized across the globe, as many countries that hosted trials of the vaccines report their own results.
The vaccine producers have also been criticized for the lack of data transparency, as none have made their Phase 3 data public or undergone peer review. This lapse has prompted Bi Jingquan, the former head of China’s drug regulator, to call on the firms to “publish all your data; it’s good for strengthening everybody’s trust,” the South China Morning Post reported.
Furthermore, the Butantan Institute in Brazil was pressured in December not to disclose the full efficacy results for Sinovac's vaccine, according to the same SCMP report.
However, companies began posting general efficacy data starting in late 2020.

In the case of Sinovac’s CoronaVac, China began the emergency use of the vaccine in August 2020 to protect high-risk groups like medical staff before conducting large-scale human trials.
Since then, Phase 3 trials in Turkey and Brazil showed the vaccine was almost 51 percent effective at preventing all COVID-19 cases among more than 12,000 health care workers treating coronavirus patients. The results prompted concern it’s ineffective compared to others on the market. When the Philippines approved the jab for emergency use, its drugs agency said it wasn’t effective enough to use in health care workers. Still, China granted CoronaVac conditional approval in February.
In early March, Turkish researchers reported that the vaccine is 83.5 percent effective, based on final analysis of fewer than 7,000 participants under the age of 59.
But new variants could be a concern: A small laboratory study, not yet been peer-reviewed, suggested last week that the Sinovac vaccine may not trigger sufficient immune responses against the Brazil variant, according to Reuters.
Then there's the Beijing/Sinopharm vaccine, which China approved for use at the end of December. The state-owned firm said it had demonstrated an 86 percent efficacy rate from a Phase 3 trial in the United Arab Emirates and a 79 percent rate in a Chinese study. Both rates were “real and valid” and simply reflect the fact that the trials used different standards for diagnosing infection and reviewing cases, according to the company.
The Wuhan/Sinopharm vaccine, on the other hand, reported an efficacy rate of 72.5 percent, citing an interim analysis of late-stage clinical trial data that it used to file for approval with Chinese regulators, which was granted at the end of February.

Meanwhile, CanSino’s viral vector vaccine was approved for emergency use on members of the military in June 2020 after early clinical data “showed some efficacy,” according to Reuters. Then, in February, interim results from more than 40,000 participants showed its overall efficacy stood at 68 percent, according to the company.
How many vaccine doses can China make?
China claims an impressive ability to produce vaccines — but it’s not clear just how much.
The fact that there are already well-established supply chains for vaccines using both inactivated viruses and viral vector technologies will count in China's favor. But in the long run, mRNA vaccines are expected to be faster to make.
“Due to the need to grow the cells at such large volumes, producing a batch could take around one month and additional time might be required to inactivate the virus, in the case of inactivated vaccines [produced in China]," Imperial College's Kis told the South China Morning Post. "Thus, for vectored vaccines and inactivated vaccines, large-scale facilities are required, access to which would be a limiting factor.”
China began mass-producing the four leading vaccines in the summer of 2020. It helps that the country is one of the largest drug producers in the world — and that medical production is largely controlled by the state, especially in Sinopharm's case.
But just how successful China will be is to be seen. In January, four of China’s many vaccine makers said they'll produce at least 2.6 billion doses this year, according to the AP. An interview with the president of the China Vaccine Industry Association in the Global Times estimated the total to be a bit lower, around 2 billion, by the end of 2021.

Sinovac’s projections have varied as well. At the end of 2020, the company said it could make roughly 300 million doses a year, but this was increased further in January to 500 million. Sinovac chairman Yin Weidong then said the company was able to double its projections to 1 billion a year thanks to an expansion in February.
As for Sinopharm, its chairman Liu Jingzhen said in late 2020 his company also would be able to make 1 billion doses by the end of 2021 — with bigger plans in sight. This month, the company said it could scale up manufacturing to make 3 billion doses per year, making it the largest vaccine producer in the world. But it wasn't clear when it could manufacture at this scale or how much of each type of vaccine it would make.
Meanwhile, CanSino said it can make approximately 500 million doses a year, according to Reuters.
Which countries are using the vaccines?
Beijing has made exporting the various vaccines — free of charge — a priority.
Not including mainland China, at least 25 countries and territories are using the jabs, according to Our World in Data. Fourteen — including Bahrain, Cambodia, Egypt, Hungary, Jordan, Macao, Morocco, Pakistan, Peru, Senegal, Serbia, Seychelles, United Arab Emirates and Zimbabwe — are deploying the Beijing/Sinopharm vaccine.
Eleven — Brazil, Chile, Guatemala, Hong Kong, Indonesia, Malaysia, Northern Cyprus, Philippines, Thailand, Turkey and Uruguay — are using Sinovac.

So far, only mainland China and the United Arab Emirates are using the Wuhan/Sinopharm vaccine, and only mainland China is using CanSino. But even these numbers are on the conservative side and should increase. Mexico, for example, approved both Sinovac and CanSino. The latter is being produced in the country, and first doses are expected in March.
However, the focus on international expansion has led to accusations that Beijing is using vaccines to score future political points with governments. It's a similar playbook to early in the pandemic, when China faced criticism for conducting "mask diplomacy" by sending the badly needed product around the world, including to EU countries.
Beijing has dismissed this claim. Guo Weimin, spokesperson for the upcoming annual top-level Chinese political meetings, called it "very narrow-minded" to "suspect that China is using vaccine exports as [an issue] to expand its geopolitical influence."
Without naming politicians such as Orbán, Guo also noted "many countries" have approved Chinese jabs, with some leaders getting the shots. "This ... shows the safety and reliability of China’s vaccines," he added.
The international focus has also raised concern that Beijing has not focused enough on vaccinating its own population. So far, the country has vaccinated about 4 percent of its people. It plans to vaccinate 40 percent of the population by mid-2021, lower than the EU benchmark of 70 percent.
The vaccines also appear to be relatively pricey in China, which could limit their uptake. Provinces are reportedly shelling out 200 yuan (roughly €26) per dose, according to the Global Times.

 

[Hypocrite-The]

COVID-19: China's 'vaccine favouritism' risks damaging global fight against pandemic, says expert
Critics have accused the nation of cherry-picking countries to donate jabs to in a bid to win political influence.

Tom Cheshire
Asia correspondent @chesh
Friday 12 March 2021 11:14, UK

But critics have accused the country of engaging in vaccine diplomacy - cherry-picking recipient countries to win political influence.

COVID-19 'vaccine diplomacy': China, Russia and India cherry-picking the countries they help

"If you choose countries where you work closer, or has strategic importance to you, then from the geopolitical perspective it can cause your competitors to go against these initiatives," Dr Jennifer Bouey, professor of health equity at Georgetown University, told Sky News.
"So some of the news we recently found is that different countries are trying to discredit each other's vaccine efficacy. From a public health perspective this is quite damaging.

Advertisement
"We're in a pandemic, we're seeing new mutated [variants] coming out, we really need to put a control on the pandemic as soon as possible.

ARTICLE CONTINUES BELOW THIS ADVERT


"So that really needs all the vaccines that are available. So either vaccine nationalism or vaccine favouritism can be damaging to this effort."
More from Covid-19

• COVID-19: A year of lockdowns that we could never have imagined
• COVID-19: Spain hopes to see summer boost in tourism as German tourists flock to Balearic Islands
• COVID-19: Boris Johnson warns Europe's third wave will hit UK - but is 'reassured' EU doesn't want jabs 'blockade'
• Transport for London accepts extension to government bailout deal to keep trains, buses and Tubes running
• COVID-19: Welsh supermarkets reopen 'non-essential' aisles as coronavirus lockdown easing continues
• COVID news live - latest UK updates: Summer holiday traffic light system mooted as new roadmap for weddings revealed

Image:China is estimated to produce 4.3 billion doses of different vaccines by the end of 2021
What stage in development are China's vaccines at?
China has been at the forefront of COVID-19 vaccine development.
It started vaccinating some citizens as far back as last summer under emergency use approval.
The country is estimated to produce 4.3 billion doses of different vaccines by the end of 2021.
The two major vaccines developed in the country are by Sinopharm and Sinovac, but another three Chinese-made vaccines are in the testing stages.
However, none of its major vaccine companies have published full clinical data for the safety and efficacy of their inoculations.

Image:Sinopharm is one of two vaccines produced by China that has been cleared for use
Only headline efficacy figures have been published. In December, state-owned company Sinopharm said its vaccine was 79% effective.
Figures for the vaccine made by Sinovac range from 50.4% to 91.25%, based on studies carried out in different countries and published by researchers there.
"The concern for now is that we haven't seen any peer reviewed publication from these phase three trials," Dr Bouey said.
"I assume eventually we'll get transparency in terms of this data."
Which countries are using Chinese vaccines?
China has made many bilateral agreements with other countries to supply vaccines. But Dr Bouey said these arrangements come with "some risk" given the lack of transparent trial data.
[IMG alt="Sinopharm's COVID-19 vaccine shipment arrives at Budapest Airport
"]https://e3.365dm.com/21/03/768x432/...pg?bypass-service-worker&20210312063555[/IMG]
Image:A delivery of China's Sinopharm vaccine arrives at Budapest Airport
Indonesia has received 38 million doses of the Sinovac vaccine, making it the single largest recipient of Chinese jabs, according to Beijing-based company Bridge Consulting.
Serbia and Hungary have also purchased Chinese vaccines, despite the latter being part of the EU's vaccination scheme.
In Africa, 12 countries have received donations from China. And most South American countries have purchased Sinovac and Sinopharm jabs.
How is China's domestic vaccine programme progressing?
At the same time as it is exporting vaccines China is also seeking to immunise its own population. According to the latest public figures, 52.52 million doses have been administered.
That means proportionally China is lagging behind the UK and US, although it does not face the same pressure to vaccinate quickly given that it has effectively controlled COVID-19.
Its population of 1.4 billion people also presents a sizeable logistics challenge.
The country aims to vaccinate 40% of its population by the end of June.

https://news.sky.com/story/covid-19...l-fight-against-pandemic-says-expert-12243343

 

[Hypocrite-The]

China approves inhaled CanSino vaccine for clinical trials - The Online Citizen Asia
China’s drug authority has approved for clinical trials an inhaled COVID-19 vaccine co-developed by domestic firm CanSino Biologics, the company said in a filing on Tuesday.
The move comes after the National Medical Products Administration gave another CanSino vaccine conditional approval last month, allowing it for public use.
China currently has five coronavirus vaccines that have been given conditional market approval or allowed for emergency use, but none of these are administered by inhalation.
CanSino said in its latest filing on the Hong Kong stock exchange that the vaccine for inhalation was jointly developed by the company and the Beijing Institute of Biotechnology, adding that their clinical trial application got the green light on Monday.
But it warned that the vaccine’s safety and efficacy remain “subject to confirmation” in trials.
As of March 20, China had administered 74.96 million coronavirus vaccine doses, according to Our World in Data, a collaboration between Oxford University and a charity.
Chinese embassies in some countries including the United States, Australia and India have issued notices saying the country will open visa applications to select people who have taken a China-made jab.
On Tuesday, a Chinese foreign ministry official said it is in “close communication” with various countries and “willing to reach mutually beneficial arrangements” to facilitate cross-border travel.
– AFP

 

[Hypocrite-The]

Hong Kong clinic punished for recommending Pfizer-BioNTech vaccine over China's Sinovac
Hong Kong is currently offering two vaccines to its residents: one from China's Sinovac, and
Hong Kong is currently offering two vaccines to its residents: One from China's Sinovac, and the other from Pfizer-BioNTech. (Photo: AFP/Paul Yeung)
24 Mar 2021 05:15PM
(Updated: 24 Mar 2021 05:23PM)
Bookmark
HONG KONG: Hong Kong health authorities have ejected a private clinic from the city's COVID-19 vaccination programme after it reportedly recommended the German-made Pfizer/BioNTech shot to patients over the one from China's Sinovac.

The move illustrates the Hong Kong government's sensitivity to any criticism of the Sinovac vaccine, which has a comparatively lower efficacy rate and was fast-tracked by regulators despite a lack of published data.

The city's health department said Tuesday (Mar 23) that the clinic would no longer administer COVID-19 jabs because a doctor violated an agreement with the inoculation programme.

Authorities said they had also reclaimed unused Sinovac doses from the clinic.

The announcement came after a photo of a notice at the clinic comparing the two vaccines' efficacy rates went viral online over the weekend.

"Advice: Don't take Sinovac, take BioNTech," the notice read, adding one of the clinic's own doctors had chosen the latter.

Ta Kung Pao, a newspaper that answers to Beijing's Liaison Office in Hong Kong, then ran a report accusing the doctor of "smearing" the Sinovac vaccine.

So far about 403,000 Hong Kongers - about 5 per cent of the city's population - have received their first doses.

More than 250,000 of them got the Sinovac jab, while the rest got Pfizer-BioNTech shots.

Separately on Wednesday, the government suspended the Pfizer shot due to a packaging problem, but stressed it did not believe there was a safety risk.

LIMITED DATA

China's COVID-19 vaccine makers have been less forthcoming than their competitors in publishing peer-reviewed data from clinical trials - even as Beijing pushes those shots around the world as an alternative to Western-made shots.

The Sinovac shot was approved by Hong Kong after the company submitted data directly to regulators, not to a peer-reviewed medical journal.

READ: HSA starts review of Sinovac COVID-19 vaccine
Data on the jab from trials in other countries points to efficacy of between 50 per cent to 80 per cent, depending on the studies, compared with Pfizer/BioNTech's 94 per cent to 95 per cent.

Hong Kong began its vaccination drive last month but the public take-up has been slow and ensnared by roiling distrust of China, fuelled by Beijing's sweeping crackdown on the city's democracy movement.

A recent poll said only 37 per cent of adults planned to get vaccinated.

Hong Kong leader Carrie Lam has previously lamented the tepid enthusiasm for vaccination and accused critics of "smearing" China's vaccines.

However, some of the city's own leading epidemiologists have openly stated that the Pfizer/BioNtech vaccine is measurably more effective.

 

[Hypocrite-The]

Will the pap just let the Chicons vaccine expire?

 

[Cottonmouth]

@syed putra Are you ready for your Chinese lessons??
They will promote you to Grab Team Lead if you can speak 3 languages.

 

[syed putra]

@syed putra Are you ready for your Chinese lessons??
They will promote you to Grab Team Lead if you can speak 3 languages.

That will mean endorsing china rule in sinkie. No way jose!

 

[Cottonmouth]

That will mean endorsing china rule in sinkie. No way jose!

You remain "road warrior"..

 

[nightsafari]

looks like China got it's hands in Malaysia already. Singapore akan datang.

 

[knowwhatyouwantinlife]

Seems like sinovac works seldom see China nationals among the daily imported cases here...on the contrary astra zebra seems to be suspended in quite a few countries

 

[Hypocrite-The]

Malaysia to give Sinovac COVID-19 vaccine to people aged 60 and above
A medical worker speaks to a man under observation after receiving the COVID-19 vaccine, at Sunway Medical Centre in Subang Jaya, Malaysia, Mar 12, 2021. (Photo: REUTERS/Lim Huey Teng)
12 Apr 2021 06:27PM
(Updated: 12 Apr 2021 06:31PM)
Bookmark
PUTRAJAYA: People aged 60 and above will be given the Sinovac vaccine under Phase 2 of Malaysia's national COVID-19 immunisation programme starting on Apr 19, said coordinating minister Khairy Jamaluddin on Monday (Apr 12).
The COVID-19 Vaccine Access Guarantee Special Committee made the decision after taking into consideration the latest data and data from other countries that showed the Sinovac vaccine is safe, effective and stable for those aged 60 and above, Mr Khairy said.
READ: Malaysia to start Phase 2 of COVID-19 vaccinations on Apr 19

Mr Khairy, who is also Science, Technology and Innovation Minister, noted that countries that have started dispensing the Sinovac vaccine to those aged 60 years and above include: Turkey, with 11 million senior citizens; Brazil, with more than 7 million recipients; and Chile, with more than 3 million people.
He said that Brazilian clinical trials and papers under review showed that the Sinovac vaccine's secondary efficacy against COVID-19 was 83.7 per cent for moderate cases and 100 per cent for severe cases.
The minister was speaking at a media conference on the development of the national immunisation programme with Health Minister Dr Adham Baba.
Mr Khairy added that 8.5 million people have registered for the COVID-19 vaccine.
The federal territories of Putrajaya and Kuala Lumpur, as well as Selangor, Penang and Negeri Sembilan recorded the highest registration in relation to the size of the population, he said.
Vaccine registration in Sabah, Kelantan, Pahang, Terengganu and Kedah is still slow, added Mr Khairy.
The minister said 31,776 appointments had been sent to Phase 2 vaccine recipients through the MySejahtera app and SMS.
From the total, 13,218 replied that they were attending, 343 replied that they would not be present, and 18,215 or 57 per cent did not confirm their attendance.
"I am urging those who have received appointment details to reply as it would enable us (to) carry out planning at vaccine centres (PPV).
"If we do not know the number turning out, there may be wastage of vaccine or insufficient vaccine doses in PPV," he said.
For those who replied that they were not attending, their appointments would be rescheduled and if they are still reluctant to attend, the government will check the reasons for their hesitation, he said.
READ: How worried should we be about links of blood clots to AstraZeneca's COVID-19 vaccine?
Asked about efforts to acquire the AstraZeneca vaccine, Mr Khairy said the matter would be decided next week after the meeting of the COVID-19 Vaccine Access Guarantee Special Committee and the reports from expert groups.
The European Medicines Agency last week said it found rare cases of blood clots among some adult recipients of the AstraZeneca vaccine, although it said the vaccine's advantages outweighed the risks.

 

[Hypocrite-The]

This is treason. Chinese schools in jiu hu should be abolished like in sinkie.

U mean fuckein schools got abolished?

 

[cocobobo]

Seems like sinovac works seldom see China nationals among the daily imported cases here...on the contrary astra zebra seems to be suspended in quite a few countries

Astra is purely political. The stats say the clot cases same % as pfizer. Europeans just want to reject all uk stuff. You want brexit? Stay out and take your vaccines with you.

 

[Hypocrite-The]

Indonesia satisfied with effectiveness of Chinese COVID-19 vaccine
Virus Outbreak China Vaccines
Chinese residents, some wearing masks, pass by a coronavirus vaccination center in Beijing on Apr 9, 2021. (Photo: AP/Ng Han Guan)
13 Apr 2021 12:02AM
(Updated: 13 Apr 2021 12:09AM)
Bookmark
BEIJING: Indonesia said on Monday (Apr 12) that it is satisfied with the effectiveness of the Sinovac coronavirus vaccine it is using, after the acknowledgement by China’s top disease control official that current vaccines offer low protection against the virus.

Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine programme, said the World Health Organization had found the Chinese vaccines had met requirements by being more than 50 per cent effective. She noted that clinical trials for the Sinovac vaccine in Indonesia showed it was 65 per cent effective.

“It means we are talking about the ability to form antibodies in our bodies is still very good,” she said.

Gao Fu, the head of the Chinese Center for Disease Control and Prevention, said at a conference Saturday that existing COVID-19 vaccines had low effectiveness rates and mixing vaccines is among strategies being considered to boost their effectiveness.

Those comments appeared to running counter to China's official narrative that has tried to promote the country’s vaccines and at times discredit its Western counterparts.

China has distributed hundreds of millions of doses of domestically made vaccines abroad and is relying on them for its own mass immunisation campaign.

Tarmizi said Indonesia would wait to see the results of any clinical trials before considering mixing vaccines.

“We are going to wait, waiting for the clinical trial to ensure the idea or innovation will have better effectiveness, immunogenicity, and efficacy level compared to the current condition,” she said.

Experts say mixing vaccines, or sequential immunisation, might boost effectiveness. Researchers in Britain are studying a possible combination of the Pfizer and the AstraZeneca vaccines.

READ: Chile defends Sinovac COVID-19 vaccine use amid fresh efficacy questions
China currently has five vaccines in use in its mass immunisation campaign, three inactivated-virus vaccines from Sinovac and Sinopharm, a one-shot vaccine from CanSino, and the last from Gao’s team in partnership with Anhui Zhifei Longcom.

The effectiveness of the vaccines range from just over 50 per cent to 79 per cent, based on what the companies have said.

Pfizer and Moderna’s vaccines, which are primarily being used in developed countries, have both been shown to be about 95 per cent effective in protecting against COVID-19 in studies.

As of Apr 2, about 34 million people in China have received the full two doses of Chinese vaccines and about 65 million received one, according to Gao.

Globally, public health experts have said that any vaccine that is 50 per cent effective would be useful, and many governments have been eager to use Chinese vaccines as rich countries around the world have snapped up shots from Pfizer and Moderna.

China’s Foreign Minister Wang Yi on Monday said that Beijing will continue to provide COVID-19 vaccines urgently needed by developing countries.

“China has provided anti-pandemic material assistance to more than 160 countries and international organisations,” Wang said at a conference to promote the image of the central city of Wuhan, where the virus was first detected in late 2019.

 

[Leckmichamarsch]

.......like after fucking Minah your lanjiao when pulled out circumcised LOL

 

[Hypocrite-The]

China's Sinovac and Sinopharm consider mixing COVID-19 vaccines, adding booster shots
Vaccine candidates have been produced by Chinese companies Sinovac Biotech and Sinopharm
Vaccine candidates have been produced by Chinese companies Sinovac Biotech and Sinopharm. (AFP/NOEL CELIS)
28 Apr 2021 03:56PM
Bookmark
TAIPEI: Chinese vaccine makers are looking at mixing their jabs and whether a booster shot could help better protect against COVID-19.

Sinovac and Sinopharm, the two Chinese manufacturers that combined have exported hundreds of millions of doses all over the world, say they are are considering combining their vaccines with those from other companies.

Earlier this month, the head of China's Center for Disease Control, Gao Fu, said that current vaccines offer low protection against the coronavirus and mixing them is among strategies being considered to boost their effectiveness.

Gao later tried to walk back his comments, saying he was talking in general about improving vaccine efficacy.

China National Biotech Group has a plan for future “sequential use” of their vaccines, Li Meng, the head of international cooperation for the company, said Wednesday at an international conference.

The company, a subsidiary of state-owned Sinopharm, made two inactivated COVID-19 vaccines and a third in clinical trials.

Sinovac, a private company based in Beijing, also said they were in preliminary discussions with investigators, including China’s Center for Disease Control, about combining the doses of their vaccine, CoronaVac, with others.

Sequential immunisation means mixing different vaccines and it is a strategy that could boost efficacy rates, said Ashley St John, an immunologist at Duke-NUS Medical School in Singapore.

“They are trying to tweak the schedule to really find the best point to give people’s vaccines,” St John said. “What’s the best combination and time point?”

READ: Indonesia satisfied with effectiveness of Chinese COVID-19 vaccine
Sinopharm's vaccines, from its Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, are 79 per cent and 72 per cent effective, respectively, the company said. It has not publicly revealed more data from the final stage of its clinical trials.

The practice is being considered in other countries as well. British scientists are studying a combo of the AstraZeneca and Pfizer shots. The study is also looking to test different intervals between doses, four weeks and 12 weeks apart.

The results of such investigations may have public health implications worldwide as governments around the world face delays in getting their vaccines in a timely manner and logistical hurdles in rolling out the shots.

READ: UK trial on switching COVID-19 vaccines adds Moderna and Novavax shots
Researchers in Brazil who conducted Sinovac’s clinical trials in the country released new data this month that reconfirmed the company’s previously announced 50 per cent efficacy rate. The paper, which has not yet been peer reviewed but was published on a website for scientists, showed that the Sinovac vaccine was 50.7 per cent effective against symptomatic COVID-19 cases and much stronger against severe disease.

CanSino, another Chinese company that has created an adenovirus-vector vaccine, said they were looking at the effects of a booster shot of their own vaccine six months after the first dose. The shot, which uses the same technology as the AstraZeneca shot, is 65.3 per cent effective.

 

[Hypocrite-The]

Khairy says Malaysians won’t be able to choose their preferred Covid-19 vaccine after all | Malay Mail​

Minister of Science, Technology and Innovation Khairy Jamaluddin speaks during a press conference at the Malaysia International Trade and Exhibition Centre in Kuala Lumpur May 30, 2021. — Picture by Firdaus Latif
Subscribe to our Telegram channel for the latest updates on news you need to know.
KUALA LUMPUR, May 30 — Vaccine recipients will not be allowed to choose the type of Covid-19 vaccine they want, as it might slow down the government’s inoculation programme and hence, such a policy would not be implemented, Science, Technology and Innovation Minister Khairy Jamaludin said today.
Khairy, who is the coordinating minister for the National Covid-19 Immunisation Programme (NIP), made the announcement just three days after his initial announcement that the option was under consideration.
“Well, that was the thinking, but right now, we are focusing on accelerating the vaccination process.
ADVERTISING
“If we allow options, maybe that will slow things down in a way. So, right now, I have decided that as far as the policy is concerned, we thought about it initially, but now the concern is to increase and ramp up the numbers, so we just give whatever we have,” he said during a press conference at the Malaysia International Trade and Exhibition Centre (Mitec) here.
On Thursday, Khairy had announced that the AstraZeneca vaccine is now back on the NIP, adding that Malaysians may also get to choose their preferred Covid-19 vaccine soon.
He said that the MySejahtera app was being updated and could include a feature that would allow recipients to indicate their vaccine preference.
He said this was being considered as Malaysia was on track to receive significant shipments of various vaccines in June and July.
Khairy explained that the government was seeking to make the national vaccination drive as frictionless as possible in order to get as many Malaysian residents vaccinated as possible.
“On the choice of vaccines, we are working out the method by which we can do this. It will be done via MySejahtera and the website. I believe this is cleaner and encourages people to use the app.
“We will be looking at how you choose your appointments, place, date as well as vaccine. If anything, we want to make the process as easy as possible for people and I’ll probably announce it in the next couple of weeks,” he added.

 

[tanwahtiu]

Oh no. Cantos are goners....but indon land cina r fuckeins. So they suck up to mandarin chicoms is no surprise

Fuckien like u isn't that good either... go fuck yrslf...